scispace - formally typeset
Search or ask a question
Institution

Catholic University of the Sacred Heart

EducationMilan, Lombardia, Italy
About: Catholic University of the Sacred Heart is a education organization based out in Milan, Lombardia, Italy. It is known for research contribution in the topics: Population & Health care. The organization has 13592 authors who have published 31048 publications receiving 853961 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: This research presents a meta-analyses of the immune system’s response to chemotherapy, which shows clear patterns of decline in the immune systems of patients with symptomatic oncologists and patients with a history of liver disease.
Abstract: a Department of Digestive and Liver Disease, Ospedale Sant’Andrea, Rome , Italy; b Department of Oncology, Royal Free University UFR Bichat-Beaujon-Louis Mourier, Colombes , France; c Digestive Oncology, University Hospital Gasthuisberg/Leuven, Leuven , Belgium; d Institute of Pathology, Catholic University – Policlinic A. Gemelli, Rome , Italy; e Department of Endocrinology, Medical University of Silesia, Katowice , Poland; f Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen , Denmark; g Department of Pathology, Tohoku University Graduate School of Medicine, Sendai , Japan; h Department of Internal Medicine and Gastroenterology, St. Orsola Hospital, University of Bologna, Bologna , Italy; i Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; j Department of Gastroenterology, Beaujon Hospital, Clichy , France

266 citations

Journal ArticleDOI
TL;DR: In this paper, the authors defined guidelines for uterine cervical cancer staging and follow-up based on the expert consensus of imaging protocols of 11 leading institutions and a critical review of the literature, and provided the radiologist with a framework for use in multidisciplinary conferences.
Abstract: Objective: To design clear guidelines for the staging and follow-up of patients with uterine cervical cancer, and to provide the radiologist with a framework for use in multidisciplinary conferences. Methods: Guidelines for uterine cervical cancer staging and follow-up were defined by the female imaging subcommittee of the ESUR (European Society of Urogenital Radiology) based on the expert consensus of imaging protocols of 11 leading institutions and a critical review of the literature. Results: The results indicated that high field Magnetic Resonance Imaging (MRI) should include at least two T2-weighted sequences in sagittal, axial oblique or coronal oblique orientation (short and long axis of the uterine cervix) of the pelvic content. Axial T1-weighted sequence is useful to detect suspicious pelvic and abdominal lymph nodes, and images from symphysis to the left renal vein are required. The intravenous administration of Gadolinium-chelates is optional but is often required for small lesions (<2 cm) and for follow-up after treatment. Diffusion-weighted sequences are optional but are recommended to help evaluate lymph nodes and to detect a residual lesion after chemoradiotherapy. Conclusions: Expert consensus and literature review lead to an optimized MRI protocol to stage uterine cervical cancer. MRI is the imaging modality of choice for preoperative staging and follow-up in patients with uterine cervical cancer.

266 citations

Journal ArticleDOI
TL;DR: Interestingly, the remodeling process appears to be more favorable in women versus men; women are more likely to present heart failure with preserved systolic function and are at greater risk for low output syndrome acutely.

264 citations

Journal ArticleDOI
16 Nov 2004-Blood
TL;DR: It is demonstrated that only sustained BCR signaling can promote survival of CLL B cells and indicate that the main difference between CLL with mutated and unmutated V(H) genes may reside in the availability of such stimulation.

264 citations

Journal ArticleDOI
16 Apr 2008-JAMA
TL;DR: Tirofiban therapy was associated with noninferior resolution of ST-segment elevation at 90 minutes following coronary intervention, whereas sirolimus-eluting stent implantation wasassociated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention.
Abstract: Context Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI). It is uncertain whether there may be similar benefits in replacing abciximab with high-dose bolus tirofiban. Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries. Objective To evaluate the effect of high-dose bolus tirofiban and of sirolimus-eluting stents as compared with abciximab infusion and uncoated-stent implantation in patients with STEMI undergoing percutaneous coronary intervention. Design, Setting, and Patients An open-label, 2 × 2 factorial trial of 745 patients presenting with STEMI or new left bundle-branch block at 16 referral centers in Italy, Spain, and Argentina between October 2004 and April 2007. Interventions High-dose bolus tirofiban vs abciximab infusion and sirolimus-eluting stent vs uncoated stent implantation. Main Outcome Measures For drug comparison, at least 50% ST-segment elevation resolution at 90 minutes postintervention with a prespecified noninferiority margin of 9% difference (relative risk, 0.89); for stent comparison, the rate of major adverse cardiac events, defined as the composite of death from any cause, reinfarction, and clinically driven target-vessel revascularization within 8 months. Results ST-segment resolution occurred in 302 of 361 patients (83.6%) who had received abciximab infusion and 308 of 361 (85.3%) who had received tirofiban infusion (relative risk, 1.020; 97.5% confidence interval, 0.958-1.086; P Conclusions In patients with STEMI undergoing percutaneous coronary intervention, compared with abciximab, tirofiban therapy was associated with noninferior resolution of ST-segment elevation at 90 minutes following coronary intervention, whereas sirolimus-eluting stent implantation was associated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention. Trial Registration clinicaltrials.gov Identifier: NCT00229515Published online March 30, 2008 (doi:10.1001/jama.299.15.joc80026).

264 citations


Authors

Showing all 13795 results

NameH-indexPapersCitations
Peter J. Barnes1941530166618
Cornelia M. van Duijn1831030146009
Dennis R. Burton16468390959
Paolo Boffetta148145593876
Massimo Antonelli130127279319
David B. Audretsch12667172456
Piero Anversa11541260220
Marco Pahor11247646549
David L. Paterson11173968485
Alfonso Caramazza10845139280
Anthony A. Amato10591157881
Stefano Pileri10063543369
Giovanni Gasbarrini9889436395
Giampaolo Merlini9668440324
Silvio Donato9686041166
Network Information
Related Institutions (5)
University of Turin
77.9K papers, 2.4M citations

95% related

University of Milan
139.7K papers, 4.6M citations

94% related

Sapienza University of Rome
155.4K papers, 4.3M citations

93% related

University of Florence
79.5K papers, 2.3M citations

93% related

University of Bologna
115.1K papers, 3.4M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023106
2022276
20213,228
20202,935
20192,170
20181,907